Drug-Induced Extrapyramidal Symptoms Scale of the Norwegian version: inter-rater and test–retest reliability

References

• Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341–356.
   PubMed Web of Science ®Google Scholar
• Divac N, Prostran M, Jakovcevski I, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:1.
   Web of Science ®Google Scholar
• Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193(4):279–288.
   PubMed Web of Science ®Google Scholar
• Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28(3):191–208.
   PubMed Web of Science ®Google Scholar
• Morrison P, Meehan T, Stomski NJ. Australian case managers' perceptions of mental health consumers use of antipsychotic medications and associated side-effects. Int J Ment Health Nurs. 2015;24(2):104–111.
   PubMed Web of Science ®Google Scholar
• Stomski NJ, Morrison P, Meyer A. Antipsychotic medication side effect assessment tools: a systematic review. Aust NZ J Psychiatry. 2016;50(5):399–409.
   PubMed Web of Science ®Google Scholar
• van Strien AM, Keijsers CJ, Derijks HJ, et al. Rating scales to measure side effects of antipsychotic medication: a systematic review. J Psychopharmacol. 2015;29(8):857–866.
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212:11–19.
   Google Scholar
• Barnes TR. The Barnes Akathisia Rating Scale – revisited. J Psychopharmacol. 2003;17(4):365–370.
   PubMed Web of Science ®Google Scholar
• Gharabawi GM, Bossie CA, Lasser RA, et al. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res. 2005;77(2–3):119–128.
   PubMed Web of Science ®Google Scholar
• Suzuki T. Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. Psychopharmacol Bull. 2011;44(1):18–31.
   PubMedGoogle Scholar
• Inada T, Yagi G, Kamijima K, et al. A statistical trial of subclassification for tardive dyskinesia. Acta Psychiatr Scand. 1990;82(6):404–407.
   PubMed Web of Science ®Google Scholar
• Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;334:1–100.
   Google Scholar
• Lindstrom E, Lewander T, Malm U, et al. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55(Suppl. 44):5–69.
   PubMed Web of Science ®Google Scholar
• Kim JH, Choi SW, Joe SH, et al. Reliability and validity of the Korean version of UKU-SERS-Pat in patients with bipolar disorder. Nord J Psychiatry. 2008;62(6):496–502.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76(2–3):247–265.
   PubMed Web of Science ®Google Scholar
• Loonen AJ, Doorschot CH, van Hemert DA, et al. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test–retest reliability and concurrent validity. Int J Neuropsychopharm. 2000;3(4):285–296.
   PubMed Web of Science ®Google Scholar
• Knol W, Keijsers CJ, Jansen PA, et al. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol. 2010;30(1):57–63.
   PubMed Web of Science ®Google Scholar
• Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage. Tokyo: Seiwa Shoten; 1996.
   Google Scholar
• Inada T, Beasley CM Jr., Tanaka Y, et al. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol. 2003;18(1):39–48.
   PubMed Web of Science ®Google Scholar
• Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002;57(2–3):227–238.
   PubMed Web of Science ®Google Scholar
• Kim JH, Jung HY, Kang UG, et al. Metric characteristics of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord. 2002;17(6):1354–1359.
   PubMed Web of Science ®Google Scholar
• Peljto A, Zamurovic L, Milovancevic MP, et al. Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian language version: inter-rater and test–retest reliability. Sci Rep. 2017;7(1):8105.
   PubMedGoogle Scholar
• Park SC, Oh HS, Tripathi A, et al. Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia. Nord J Psychiatry. 2019;73(6):323–330.
   PubMed Web of Science ®Google Scholar
• Inada T. DIEPSS: second generation rating scale for antipsychotic induced extrapyramidal symptoms drug induced extrapyramidal symptoms scale. Tokyo: Seiwa Shoten Publishers; 2009.
   Google Scholar
• Giraudeau B, Mary JY. Planning a reproducibility study: how many subjects and how many replicates per subject for an expected width of the 95 per cent confidence interval of the intraclass correlation coefficient. Stat Med. 2001;20(21):3205–3214.
   PubMed Web of Science ®Google Scholar
• Bartko JJ, Carpenter WT Jr. On the methods and theory of reliability. J Nerv Ment Dis. 1976;163(5):307–317.
   PubMed Web of Science ®Google Scholar
• Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.
   PubMed Web of Science ®Google Scholar
• Ormerod S, McDowell SE, Coleman JJ, et al. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf. 2008;31(7):597–607.
   PubMed Web of Science ®Google Scholar
• Inada T, Ohnishi K, Kamisada M, et al. A prospective study of tardive dyskinesia in Japan. Eur Arch Psychiatry Clin Neurosci. 1991;240(4–5):250–254.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Fleischhacker WW, Peuskens J, et al. SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): the development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Ther Adv Psychopharmacol. 2014;4(1):15–21.
   PubMedGoogle Scholar
• Marx RG, Menezes A, Horovitz L, et al. A comparison of two time intervals for test–retest reliability of health status instruments. J Clin Epidemiol. 2003;56(8):730–735.
   PubMed Web of Science ®Google Scholar